Minutia is pioneering advancements in cell therapy, specifically targeting diabetes through the development of insulin-producing cell transplants. The company aims to enhance the robustness and control of these transplants, integrating nanosensors that allow for real-time monitoring of the cells in vivo. This innovative approach is designed to significantly improve the management of diabetes and the efficacy of cell replacement therapies, potentially transforming the clinical landscape for patients suffering from this condition.

In addition to their core technology, Minutia has garnered substantial support from various funding bodies, including grants from the National Institutes of Health and the California Institute for Regenerative Medicine. These financial resources are aimed at furthering their research and development efforts, particularly in creating a real-time monitoring platform for their cell therapies. The company has also been recognized within the scientific community, participating in initiatives such as the T1D Moonshot Community and receiving accolades for their contributions to diabetes innovation.

United States

We are working towards a transplant of insulin producing cells combined with nanosensors for diabetes that is so safe and effective we would put it in our own bodies and the bodies of people we love.

We believe our ability to create more robust and controlled insulin producing cell transplants that can be monitored in vivo over time will revolutionize the current clinical landscape for diabetes and cell replacement therapy.

Minutia

Company Details